Trial Profile
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2020
Price :
$35
*
At a glance
- Drugs MEDI 7510 (Primary) ; Influenza virus vaccine
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors MedImmune
- 01 Feb 2020 Results assessing efficacy endpoints for a Phase IIb study of a respiratory syncytial virus vaccine in older adults using patient-reported outcomes with laboratory confirmation published in the Value in Health
- 23 Sep 2017 Results published in the Journal of Infectious Diseases.
- 08 Dec 2016 Status changed from active, no longer recruiting to discontinued due to failure to meet the primary efficacy endpoint.